Subscribe To
NUVB / FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

NUVB News

By Zacks Investment Research
January 21, 2022
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types f more_horizontal

By Zacks Investment Research
January 21, 2022
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types f more_horizontal

By Zacks Investment Research
January 21, 2022
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types f more_horizontal

By Benzinga
January 20, 2022
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumor more_horizontal

By Benzinga
January 20, 2022
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumor more_horizontal

By Benzinga
January 20, 2022
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumor more_horizontal